Galapagos is flush with billions in cash, but it’s not moving forward with its own pipeline. So what’s the Belgian biotech going to do with

BioMarin plans to dish out $4.8 billion to acquire Amicus Therapeutics and its two approved rare disease medicines, the California biotech said Friday. By gaining

Sens. Bernie Sanders (I-VT) and Markwayne Mullin (R-OK) are not seeing eye to eye on why the Senate failed to pass legislation reauthorizing the FDA’s

Plus, news on: EpimAb, Boehringer and Nxera, Syneron, Amphix Altimmune goes to Phase 3 in MASH: The drug developer’s Phase 2 trial of pemvidutide, a

Aditum Bio, the biotech company creation firm from former Novartis leaders Joe Jimenez and Mark Fishman, has returned to China for another deal. This time,